Peptides derived from HIV-1 Vif: A non-substrate based novel type of HIV-1 protease inhibitors

Journal of Molecular Biology

Volumn 287, Issue 1, 1999, Pages 93-101

  Friedler, Assaf ^a   Blumenzweig, Immanuel ^a   Baraz, Lea ^a   Steinitz, Michael ^a   Kotler, Moshe ^a   Gilon, Chaim ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Aspartic protease inhibitor; HIV 1; HIV PR; Peptide mapping; Vif

Indexed keywords

PEPSIN A; PROTEINASE; PROTEINASE INHIBITOR; VIF PROTEIN; VIRUS PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME INHIBITION; ENZYME SUBUNIT; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; ROUS SARCOMA ONCOVIRUS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; ONCOVIRINAE; RNA VIRUSES; ROUS SARCOMA VIRUS;

EID: 0033582949     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1998.2585     Document Type: Article

References (39)

1. Arad G., Almog N., Bar-Meir R., Chorev M., Kotler M. Avian sarcoma leukemia virus protease linked to the adjacent gag polyprotein is enzymatically active. Virology. 214:1995;439-444.
2. Baraz L., Friedler A., Blumenzweig I., Nussinov O., Chen N., Steinitz M., Gilon C., Kotler M. Human immunodeficiency virus type 1 Vif derived peptides inhibit the viral protease and arrest virus production. FEBS Letters. 441:1998;419-426.
3. Bragman K. Saquinavir: an HIV proteinase inhibitor. Advan. Exp. Med. Biol. 394:1996;305-317.
4. Byk G., Halle D., Zeltser I., Bitan G., Selinger Z., Gilon C. Synthesis and biological activity of NK-1 selective N-backbone cyclic analogs of the C-terminal hexapeptide of substance P. J. Med. Chem. 39:1996;3174.
5. Camur D., Trono D. Characterization of HIV-1 vif particle incorporaton. J. Virol. 70:1996;6106-6111.
6. Chowdhury L. H., Chao W., Potash M. J., Sova P., Gendelman H. E., Volsky D. J. Vif-negative human immunodeficiency virus type 1 persistently replicates in primary macrophages producing attenuated progeny virus. J. Virol. 70:1996;5336-5345.
7. Coffin J. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 267:1995;483-489.
8. Cullen B. R. HIV-1 auxiliary proteins: making connections in a dying cell. Cell. 93:1998;685-692.
9. Deeks S. G., Smith M., Holodniy M., Kahn J. O. HIV-1 protease inhibitors: a review for clinicians. J. Am. Med. Assoc. 277:1997;145-153.
10. Emerman M., Malim M. H. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science. 280:1998;1880-1884.
11. Erickson J. W., Burt S. K. Structural mechanisms of HIV drug resistance. Annu. Rev. Pharmacol. Toxicol. 36:1996;545-571.
12. Friedler A., Zakai N., Karni O., Broder Y. C., Baraz L., Kotler M., Loyter A., Gilon C. Backbone cyclic peptide, which mimics the Nuclear Localization Signal of HIV-1 MA, inhibits nuclear import and virus production in non-dividing cells. Biochemistry. 37:1998;5616-5622.
13. Gilon C., Halle D., Chorev M., Selinger Z., Byk G. Backbone cyclization: a new method for conferring conformational constraint on peptides. Biopolymers. 31:1991;745-750.
14. Gilon C., Muller D., Bitan G., Salitra Y., Goldwasser I., Hornik A. Cycloscan: conformational libraries of backbone cyclic peptides. Proceedings of the 24th European Peptide Symposium. 1996;Mayflower Scientific Ltd, Edinburgh.
15. Goncalves J., Jallepalli P., Gabuzda D. H. Subcellular localization of the vif protein of human immunodeficiency virus type 1. J. Virol. 68:1994;704-712.
16. Han Q., Chang C. H., Li R., Ru Y., Jadhav P. K., Lam P. Y. S. Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole p2/p2′ cyclic ureas with improved potency. J. Med. Chem. 41:1998;2019-2028.
17. Jarvis B., Faulds D. Nelfinavir: a review of its therapeutic efficacy in HIV infection. Drugs. 56:1998;147-167.
18. Jaskolski M., Tmasselli A. G., Sawyer T. K., Staples D. G., Heinrikson R. L., Schneider J., Kent S. B. H., Wlodawer A. Structure at 2.5 Å resolution of chemically synthesized HIV-1 protease complexed with a hydroxyethylene-based inhibitor. Biochemistry. 30:1991;1600-1609.
19. Kiso Y. Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere. Biopolymers. 40:1996;235-244.
20. Klabe R. M., Bacheler L. T., Ala P. J., Erickson-Viitanen S., Meek J. L. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency. Biochemistry. 37:1998;8735-8742.
21. Kotler M., Katz R. A., Danho W., Leis J., Skalka A. M. Synthetic peptides as substrates and inhibitors of a retroviral protease. Proc. Natl Acad. Sci. USA. 85:1988;4185-4189.
22. Kotler M., Arad G., Huges S. H. HIV-1 Gag-protease fusion proteins are enzymatically active. J. Virol. 66:1992;6781-6783.
23. Kotler M., Simm M., Zhao Y. S., Sova P., Chao W., Ohnona S. F., Roller R., Krachmarov C., Potash M. J., Volsky D. J. Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro. J. Virol. 71:1997;5774-5781.
24. Lea A. P., Faulds D. Ritonavir. Drugs. 52:1996;541-546.
25. Liu H., Wu X., Newman M., Shaw G., Hahn B., Kappes J. The vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures. J. Virol. 69:1995;7630-7638.
26. Matayoshi E. D., Wang G. T., Krafft G. A., Erickson J. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science. 247:1990;954-958.
27. Miller R. H., Sarver N. HIV accessory proeins as therapeutic targets. Nature Med. 3:1997;389-394.
28. Navia M. A., Fitzgerald P. M. D., McKeever B. M., Leu C. T., Heimbach J. C., Herber W. K., Sigal I. S., Darke P. L., Springer J. P. Three-dimensional structure of aspartyl protease from HIV-1. Nature. 337:1989;615-620.
29. Oroszlan S., Luftig R. B. Retroviral proteinases. Curr. Top. Microbiol. 157:1990;153-185.
30. Ratner L., Haseltine W., Patarca R., Livak K. J., Starcich S., Joseph S. F., Doran E. R., Rafalski J. A., Whitehorn K. B., Ivanoff L., Pearson M. L., Lauterberg J. A., Papas T. S., Ghrayeb J., Chang N. T. et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature. 313:1985;277-284.
31. Reid R. C., Fairlie D. P. Mimicking extended conformations of protease substrates: designing cyclic peptidomimetics to inhibit HIV-1 protease. Advan. Amino Acid Mimetics Peptidomimetics. 1:1997;77-107.
32. Roberts N. A., Martin J., Kinchington D., Broadhurst A. V., Craig J. C., Duncan I., Galpin S. A., Handa B. K., Kay J., Krohn A., Lambert R. W., Merrett J. H., Mills J. S., Parks K. E. B., Redshaw S., Taylor D. L. et al. Rational design of peptide-based HIV proteinase inhibitors. Science. 248:1990;358-361.
33. Silva A. M., Cachau R. E., Sham H. L., Erickson J. W. Inhibition and catalytic mechanism of HIV-1 aspartic protease. J. Mol. Biol. 255:1996;321-346.
34. Simm M., Shahabuddin M., Chao W., Allan J. S., Volsky D. J. Aberrant Gag protein composition of human immunodeficiency virus type 1 vif mutants produced in lymphocytes. J. Virol. 69:1995;4582-4586.
35. Tomasselli A. G., Howe W. J., Sawyer T. K., Wlodawer A., Heinrikson R. L. The complexities of AIDS: an assessment of the HIV protease as a therapeutic target. Chim. Oggi. 5:1991;6-27.
36. Trono D. HIV accessory proteins: leading roles for the supporting cast. Cell. 82:1995;189-192.
37. Von-Schwedler U., Song J., Aiken C., Trono D. Vif is crucial for HIV-1 provural DNA synthesis in infected cells. J. Virol. 67:1993;4945-4955.
38. Wei X., Ghosh S. K., Taylor M. E., Johnson V. A., Emini E. A., Deutch P., Lifsori J. D., Bonhoeffer S., Nowak M. A., Hahn B. A., Saag M. S., Shaw G. M. Viral dynamics in HIV-1 infection. Nature. 373:1995;117-122.
39. West M. L., Fairlie D. P. Targeting HIV-1 protease: a test of drug-design methodologies. Trends Pharm. Sci. 16:1995;67-75.